Alex Vo

660 total citations
14 papers, 500 citations indexed

About

Alex Vo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alex Vo has authored 14 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alex Vo's work include Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Treatments and Mutations (3 papers). Alex Vo is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Treatments and Mutations (3 papers). Alex Vo collaborates with scholars based in United States and Canada. Alex Vo's co-authors include Jorge Chaves, Virginia F. Borges, Alison Conlin, Marc C. Chamberlain, Todd Gray, Erika Hamilton, Diana F. Hausman, Scott Peterson, Daniel W. Bowles and Rashmi K. Murthy and has published in prestigious journals such as The Lancet Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Alex Vo

13 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alex Vo United States	8	302	228	219	105	102	14	500
Luke Walker United States	10	272 0.9×	255 1.1×	253 1.2×	59 0.6×	90 0.9×	39	489
Amy Tilley United States	5	309 1.0×	207 0.9×	106 0.5×	111 1.1×	39 0.4×	5	444
Ilana Schlam United States	11	324 1.1×	142 0.6×	162 0.7×	116 1.1×	53 0.5×	41	535
Cath Trigwell United Kingdom	6	150 0.5×	136 0.6×	220 1.0×	42 0.4×	53 0.5×	9	365
Jin Meng China	13	150 0.5×	108 0.5×	89 0.4×	103 1.0×	75 0.7×	24	417
Prateek Mendiratta United States	13	240 0.8×	256 1.1×	184 0.8×	57 0.5×	103 1.0×	37	584
Emanuela Risi Italy	15	411 1.4×	378 1.7×	238 1.1×	51 0.5×	86 0.8×	39	673
Anne Patsouris France	12	279 0.9×	153 0.7×	142 0.6×	63 0.6×	40 0.4×	52	426
Jennifer Foglietta Italy	10	283 0.9×	162 0.7×	108 0.5×	66 0.6×	36 0.4×	20	413
L. Hart United States	11	254 0.8×	183 0.8×	220 1.0×	22 0.2×	43 0.4×	25	518

Countries citing papers authored by Alex Vo

Since Specialization

Citations

This map shows the geographic impact of Alex Vo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Vo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Vo more than expected).

Fields of papers citing papers by Alex Vo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Vo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Vo. The network helps show where Alex Vo may publish in the future.

Co-authorship network of co-authors of Alex Vo

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Vo. A scholar is included among the top collaborators of Alex Vo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Vo. Alex Vo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Miao, Bo, Yogesh Yadav, Jurriaan H. de Groot, et al.. (2024). P10.06.A AGENT-BASED MODELING FOR PATIENT-CENTERED CLINICAL DECISION SUPPORT IN NEURO-ONCOLOGY. Neuro-Oncology. 26(Supplement_5). v56–v56.

Tseng, Tzu-Liang, et al.. (2024). Machine-Learning-Enabled Diagnostics with Improved Visualization of Disease Lesions in Chest X-ray Images. Diagnostics. 14(16). 1699–1699. 3 indexed citations

Sun, Hao, Larry C. Wienkers, Alice Chin, et al.. (2022). Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl. Cancer Chemotherapy and Pharmacology. 89(6). 737–750. 11 indexed citations

Zhuang, Yan, et al.. (2022). Improving lung region segmentation accuracy in chest X-ray images using a two-model deep learning ensemble approach. Journal of Visual Communication and Image Representation. 85. 103521–103521. 18 indexed citations

Murthy, Rashmi K., Virginia F. Borges, Alison Conlin, et al.. (2018). Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. The Lancet Oncology. 19(7). 880–888. 129 indexed citations

Borges, Virginia F., Cristiano Ferrario, Nathalie Aucoin, et al.. (2018). Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer. JAMA Oncology. 4(9). 1214–1214. 117 indexed citations

Vo, Alex, et al.. (2017). Evaluation of drug-drug interactions (DDI) between tucatinib and capecitabine (C) in patients with advanced HER2+ metastatic breast cancer from a phase 1b study. Annals of Oncology. 28. v98–v98. 1 indexed citations

Vo, Alex, Luke Walker, Diana F. Hausman, & Scott Peterson. (2015). Abstract B152: Clinical pharmacokinetics of an improved tablet formulation of ONT-380 in HER2+ metastatic breast cancer patients. Molecular Cancer Therapeutics. 14(12_Supplement_2). B152–B152. 2 indexed citations

Bowles, Daniel W., Neil Senzer, Diana F. Hausman, et al.. (2014). A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs. 32(6). 1197–1203. 19 indexed citations

10.

Bowles, Daniel W., Neil Senzer, Julie R. Brahmer, et al.. (2013). A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. British Journal of Cancer. 109(5). 1085–1092. 53 indexed citations

11.

Nemunaitis, John, Cynthia Bedell, Kevin Klucher, Alex Vo, & Sam H. Whiting. (2013). Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer. Journal for ImmunoTherapy of Cancer. 1(S1). 11 indexed citations

12.

Hong, David S., Daniel W. Bowles, Gerald S. Falchook, et al.. (2012). A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(15). 4173–4182. 134 indexed citations

13.

Senzer, Neil, Daniel W. Bowles, Roger B. Cohen, et al.. (2011). Abstract A174: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and cetuximab.. Molecular Cancer Therapeutics. 10(11_Supplement). A174–A174. 1 indexed citations

14.

Jimeno, Antonio, Neil Senzer, Wen Wee, et al.. (2011). Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel.. Molecular Cancer Therapeutics. 10(11_Supplement). A170–A170. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact